Bristol-Myers Squibb vs Tata Motors: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Tata Motors was founded in 1945 by J.R.D. Tata, Sumant Moolgaokar and is led by Girish Wagh.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Tata Motors
- Founded
- 1945
- Headquarters
- Mumbai, Maharashtra, India
- Current CEO
- Girish Wagh
- Employees
- 40,578
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Tata Motors
J.R.D. Tata
J.R.D. Tata chaired the Tata Group from 1938 to 1991 and founded Tata Engineering and Locomotive Company (TELCO) in 1945 to build locomotives and engineering products.
Sumant Moolgaokar
Sumant Moolgaokar was the engineer who ran TELCO for decades and built its manufacturing base, including the Pune plant and research capability. He is often called the architect of Tata Motors, and the Tata Sumo was named after him.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Tata Motors
- Ratan Tata1991–2012
Former Chairman
He transformed Tata Motors from a domestic truck manufacturer into a globally recognized automotive powerhouse, cementing its presence in the premium luxury sector.
Source - N. Chandrasekaran2017–present
Chairman
As Chairman, he stabilized Jaguar Land Rover's severe cash burn during the semiconductor crisis and secured Tata Motors' absolute dominance in the early Indian EV market.
Source - Girish Wagh2025–present
Managing Director and CEO
Wagh leads the post-demerger company, which reported FY2026 revenue of ~$9.73B (INR83,855 Cr) and Q1 FY2027 wholesales of 108,700 units, and is driving the Iveco acquisition. He previously headed Tata's commercial-vehicle business as an executive director.
Source - G.V. Ramanan2025–present
Chief Financial Officer
He helped maintain Tata's absolute monopoly in the heavy commercial vehicle segment against rising international competition.
Source
Timeline: Bristol-Myers Squibb and Tata Motors side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1945Tata Motors
TELCO is founded
Tata Engineering and Locomotive Company is established, forming the roots of Tata Motors.
1954Tata Motors
Commercial vehicle production begins
Tata enters commercial-vehicle production through a collaboration with Daimler-Benz.
1954Tata Motors
First Indian-Built Commercial Vehicle
TELCO produces its first commercial vehicle in collaboration with Daimler-Benz, marking India's entry into domestic truck manufacturing.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
1998Tata Motors
Tata Indica Launches
Tata Motors launches the Indica, its first indigenously designed passenger car, marking a major expansion beyond commercial vehicles.
2004Tata Motors
Daewoo commercial vehicle business acquired
Tata Motors acquires Daewoo Commercial Vehicle in South Korea, expanding heavy-truck capabilities.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2008Tata Motors
Jaguar Land Rover acquired
Tata Motors acquires Jaguar Land Rover from Ford, transforming old Tata Motors into a global automaker.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2023Tata Motors
Sanand plant acquisition completed
Tata Passenger Electric Mobility completes the acquisition of Ford India's Sanand plant.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2024Tata Motors
Ratan Tata Dies
Ratan Tata, the Tata Group chairman who led the transformative Jaguar Land Rover acquisition, dies in October 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Tata Motors
Demerger takes effect
The composite scheme separates commercial vehicles from passenger vehicles and JLR, changing the current Tata Motors Ltd perimeter.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026Tata Motors
FY2026 revenue is reported
Current Tata Motors Limited reports FY2026 consolidated revenue of ~$9.73B (INR83,855 Cr).
2026Tata Motors
Iveco tender offer launched
After Consob approval, Tata Motors launches a EUR14.10-per-share all-cash offer for Iveco Group, open September 7 to October 26, 2026.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Tata Motors
- Iveco Group2026$4.4B
- Ford India Sanand plant2023Undisclosed
- Jaguar Land Rover2008$2.3B
- Daewoo Commercial Vehicle2004Undisclosed
Questions about Bristol-Myers Squibb vs Tata Motors
Who is the CEO of Bristol-Myers Squibb Company and Tata Motors Limited?
Bristol-Myers Squibb Company is led by Christopher Boerner and Tata Motors Limited is led by Girish Wagh. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Tata Motors Limited?
Bristol-Myers Squibb Company was founded in 1887 — 58 years before Tata Motors Limited, which was founded in 1945. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Tata Motors Limited.
How many employees does Bristol-Myers Squibb Company have compared to Tata Motors Limited?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Tata Motors Limited employs approximately 40,578. Tata Motors Limited has the larger workforce at 40,578 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Tata Motors Limited headquartered?
Bristol-Myers Squibb Company is headquartered in United States and Tata Motors Limited is headquartered in India. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Bristol-Myers Squibb Company and Tata Motors Limited?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Tata Motors Limited was founded by J.R.D. Tata, Sumant Moolgaokar.
Which company has a longer operating history — Bristol-Myers Squibb Company or Tata Motors Limited?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Tata Motors Limited has been in operation for around 81 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Tata Motors overview